I American College of Chest Physicians for inviting me to join you here today, to discuss certain issues bearing on the Food and Drug Administration and its performance. Certainly, we have many things to discuss.
For example, of all I heard about the so-called 'drug lag" when I was in Washington, I heard most about beclomethasone and the apparent slowness with which that drug appeared on the American market. While to many of you the FDA may have seemed somewhat defensive about the 'dmg lag," the Agency, and I as part of it, felt somewhat ill-used and put-upon by a good bit of what has been said on this subject. The ingredients of the "drug lag" issue include not only that some drugs appear in the United Kingdom or other countries before they are marketed in the US, but also that drug research and production are moving overseas, that drug research is being slowed down, that drug research is becoming too expensive to do, and that the costlbenefit ratio of the new drug regulatory process has gotten too high. The blame for all of this is usually laid directly on FDA's doorstep. No one talks about the costs of labor, equipment or construction in this country as opposed to countries overseas. No one talks about our high ethical standards or our requirement for Institutional Review Committees, or the many rules for protecting our experimental subjects. The only apparent concern is over FDA's regulations and FDA's alleged reluctance to accept the results of less than perfect clinical trials.
But I have heard few people ever ask why FDA behaves as it does-whether FDA's rules and regulations faithfully d e c t the mandates of the Food, D N~ and Cosmetic Aa, or are really FDA's arbitrary extension of authority it doesn't legally possess.
As the person who ultimately has been responsible for FDA's policies and behavior during the past few years, I welcome this opportunity to try to explain what we have been hying to do with the new drug review process. I will pay particular regard to clinical trials, to our guidelines for clinical trials, the meaning of these guidelines, and the importance of clinical trials to the new drug approval process. I hope I might be excused for having some strong feelings about these subjects-feelings developed to CHEST 73: 6, JUNE, 1978 SUPPLEMENT some extent by my scientific training, but 6 x 4 by dozens of appearances before Congressional committees. If you read newspapers, you must know that FDA, with increasing frequency, is hauled before Congress to explain some misadventure with one or another drug. I wince inwardly as I recall some of these painful experiences. As I refresh your memories by reciting a short Lisf consider the relationship of the problems to the controlled clinical trial.
Early in my career as Commissioner came the Dalkon Shield controversy and the resulting Congressional hearings, which ended only with the disappearance of this intrauterine device. Was it really less safe or less effective than others, more safe and effective, or the same? There were no trials, so no one will ever know, with certainty. Nexf I recall chymopapain, the enzyme injected into ruptured intervertebral disks. No controlled trials had been done, although FDA had reports of 10,000 cases done in this -try.
When a good placebo-controlled study was done just as we were about to approve the drug, we learned that chymopapain and the placebo control were equally effective-or equally ineffective.
Repeated Congressional hearings have explored whether the oral hypoglycemic agents should remain on the market. Central to this decision is the design and control of the UGDP study. We discussed with Congress whether the amphetamines are effective for treating obesity; whether propranolol was actually responsible for the lessening of angina pectoris; whether Flagyl was too toxic; whetiier estrogens were safe and effective as contraceptives-either before or after intercourse, and on and on.
In 'All methods of research reasonably applicable," "Full reports," " F d l listing," "Full statements," ' F d description," "False or misleading in any particular.' I can assure you that to anyone given the responsibility for enforcing this law, it is obvious that the standards set in the law are high, and that these high standards must be reflected in FDA's regulations.
Furthermore, as I have learned through repeated experience, if one is asked by a Congressional committee why a particular drug was approved, and then told that in the view of the lawmakers, the approval was improper or even illegal, then one quickly learns to interpret the law and to write regulations with great care and a degree of strictness.
The practical results of all this have been both good and bad. There is no question in my mind that our drug supply is the safest in the world, and that FDA has exercised commendable caution in canying out its responsibility to protect the American consumer. The other side of the coin is that the judgments FDA must make are extremely di5cult and complex, and often have to be made in the absence of definitive data of one kind or another.
It has long been my view that FDA could be fairly criticized for two specific aspects of how it went about the new drug review process. Further, it has been the policy of the agency to insist upon controlled trials when controls are feasible, randomization of subjects when that is at all possible, and for the trial to be blinded when this is feasible. The rub, of course, comes in deciding what is really possible or feasible, in any given circumstance.
I have now, of course, got to the interesting question of the meaning of, and the pmper degree of specificity of guidelines for clinical trials. Guidelines are simply strong suggestions, and not inviolate rules. I think everyone can understand that. Yet, I
noted in reviewing advisory committee discussions about the guidelines for clinical testing of bmnchodilator drugs that fears were expressed, to quote a member of the advisory committee, that the "guidelines would become gospel." And because of this concern, the guidelines were, in places, made quite general and nonspeci6c. I believe that in becoming less specific, they became of less practical value.
It is my strong belief that guidelines for clinical trials should be detailed and spedfic, and should speak directly to the purposes of the trial, the design and conduct of the study, the methods of study experts consider adequate, and even the reoommended ways to handle data. If guidelines for clinical trials are made comprehensive and complete, they will then be of maximum use in upgrading the quality of the research done in the drug field, and that is a desirable outcome. And if a scientist wishes to do otherwise than suggested by the guidelines, he or she obviously can, and this should be made clear in the guidelines. But the guidelines should be explicit about what experts believe to be best The scientist who does something else is obligated to know why he or she is straying from the guidelines, and should so state in the research protocol.
If guidelines state only that controls should be "adequate," without defining what type of controls experts believe to be possible and desirable and thus adequate in that circumstance, then the guidelines really aren't as useful as they ought to be. And I would remind you of a point I made earlier. In a real sense, guidelines for clinical trials are criteria for FDA decision-making. Thus, the more speci6c you are in framing these guidelines, the more impact you are having on FDA's decisions about new drugs. I will comment bridy on one other aspect of guidelines for clinical research. FDA has learned from recent experience something most scientists know, but forget-the importance of placebo control. Our experience with chymopapain demonstrated that at times it is far more ethical, not to mention scientific, to use a placebo control than to try to avoid it in the belief that placebo therapy of an CHEST 73: 6, JUNE, 1978 SUPPLEMENT
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illness is unethical. And the same goes for the use of a similar, proven effective drug as a second type of control. I t is foolish, and will prove shortsighted, t o by to avoid the use of such controls.
The weakest part of our knowledge about the proper use of drugs concerns the post-approval period-the longterm safety and effectiveness of drugs, the incidence and kinds of adverse drug reactions, drug-drug interactions, and the effect of drugs on pregnant women and children. In the future, clinical trials will have to be so designed that these questions can be answered. This will obviously require that clinical trials become longer in duration, larger in size, and more complex. I would guess that in the future, FDA will be asked by Congress to judge the relative safety, and the relative effectiveness, of groups of drugs. FDA does this now, t o some extent, as with the sequential contraceptives, which were removed from the market as less safe and less effective than the standard "pill." But FDA's making such judgments will force clinical trials to b e larger, longer and more numerous.
In this oveniew of a very large subject I have tried to impress upon you that FDA has changed how it goes about the drug review process. FDA is opening u p its procedures; it is going public. FDA is inviting you to participate, to become a part of the system. I believe that FDA has become very responsive to people who know how t o approach the Agency, and t o people who are willing to do so. Clindnmycin and lincomycin are examples of drugs that are too frequently used, have serious and even lethal side effects, and are needed by a relatively small percentage of those for w b m it is now pmcribed. Phenformin is another example. Theoretically, that drug could remain legally available for those who really need it, but would not be available for the run-of-tbe-mill patient for whom it is essentially mntraindicated.
In the futnre, the drug review pnress in this country is not likely to h e simpler or easier, but more m p l e x .
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